| Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial JS De Bono, S Oudard, M Ozguroglu, S Hansen, JP Machiels, I Kocak, ... The Lancet 376 (9747), 1147-1154, 2010 | 3966 | 2010 |
| Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study EEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, ... The Lancet 393 (10167), 156-167, 2019 | 1336 | 2019 |
| Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial G Gravis, K Fizazi, F Joly, S Oudard, F Priou, B Esterni, I Latorzeff, ... The lancet oncology 14 (2), 149-158, 2013 | 871 | 2013 |
| Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2 … JPH Machiels, RT Reilly, LA Emens, AM Ercolini, RY Lei, D Weintraub, ... Cancer research 61 (9), 3689-3697, 2001 | 552 | 2001 |
| Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up JP Machiels, CR Leemans, W Golusinski, C Grau, L Licitra, V Gregoire Annals of Oncology 31 (11), 1462-1475, 2020 | 510 | 2020 |
| Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response AM Ercolini, BH Ladle, EA Manning, LW Pfannenstiel, TD Armstrong, ... The Journal of experimental medicine 201 (10), 1591-1602, 2005 | 480 | 2005 |
| Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum … JPH Machiels, RI Haddad, J Fayette, LF Licitra, M Tahara, JB Vermorken, ... The Lancet Oncology 16 (5), 583-594, 2015 | 461* | 2015 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 402 | 2021 |
| Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer KJ Pienta, JP Machiels, D Schrijvers, B Alekseev, M Shkolnik, SJ Crabb, ... Investigational new drugs 31, 760-768, 2013 | 400 | 2013 |
| Trastuzumab for patients with axillary-node–positive breast cancer: results of the FNCLCC-PACS 04 trial M Spielmann, H Roché, T Delozier, JL Canon, G Romieu, H Bourgeois, ... Journal of Clinical Oncology 27 (36), 6129-6134, 2009 | 370 | 2009 |
| Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in … FE Lecouvet, J El Mouedden, L Collette, E Coche, E Danse, F Jamar, ... European urology 62 (1), 68-75, 2012 | 355 | 2012 |
| Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma TE Hutson, ID Davis, JPH Machiels, PL De Souza, S Rottey, B Hong, ... Journal of Clinical Oncology 28 (3), 475-480, 2010 | 353 | 2010 |
| Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial RW Naumann, A Hollebecque, T Meyer, MJ Devlin, A Oaknin, J Kerger, ... Journal of Clinical Oncology 37 (31), 2825, 2019 | 340 | 2019 |
| Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus G Curigliano, S Banerjee, A Cervantes, MC Garassino, P Garrido, ... Annals of Oncology 31 (10), 1320-1335, 2020 | 304 | 2020 |
| HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice RT Reilly, MBC Gottlieb, AM Ercolini, JPH Machiels, CE Kane, FI Okoye, ... Cancer research 60 (13), 3569-3576, 2000 | 301 | 2000 |
| Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis P Forget, J Vandenhende, M Berliere, JP Machiels, B Nussbaum, ... Anesthesia & Analgesia 110 (6), 1630-1635, 2010 | 273 | 2010 |
| A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma C Wülfing, JPH Machiels, DJ Richel, MO Grimm, U Treiber, MR De Groot, ... Cancer 115 (13), 2881-2890, 2009 | 261 | 2009 |
| Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of … JP Machiels, S Subramanian, A Ruzsa, G Repassy, I Lifirenko, A Flygare, ... The lancet oncology 12 (4), 333-343, 2011 | 257 | 2011 |
| Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival B Mlecnik, M Van den Eynde, G Bindea, SE Church, A Vasaturo, ... JNCI: Journal of the National Cancer Institute 110 (1), 97-108, 2018 | 242 | 2018 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised … DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ... The Lancet 390 (10109), 2266-2277, 2017 | 239 | 2017 |
